Clover : Changes to Board of Directors

Clover Corporation Limited

ABN 85 003 622 866

20 October 2020

Clover Corporation Limited - Changes to the Board of Directors

Clover Corporation Limited (ASX: CLV) (Clover or Company) advises of planned succession changes to the Board of Directors. Dr. Merilyn Sleigh and Ms. Cheryl Hayman who have been Non-Executive Directors for the past 12 years are standing down from the Board. Merilyn has resigned effective today and Cheryl who is due to retire at the Company's upcoming annual general meeting has decided not to stand for re-election.

Non-Executive Chairman, Rupert Harrington, said "The Board thanks Merilyn and Cheryl for their significant and committed contribution over the past 12 years as Clover has grown through the expansion of its commercial base and its sales particularly to international markets. They have carried out their duties with the utmost professionalism and we wish them well in their endeavours."

Merilyn has provided the Board and Company with her expertise in R&D and business development. She has chaired the Remuneration Committee and served on the Nominations and Audit & Risk Committees.

Cheryl has contributed with her strong business development and marketing expertise. She chaired the Nominations Committee and served on the Remuneration and Audit & Risk Committees.

Clover is pleased to announce the appointment of two Non-Executive Directors effective today - Ms. Toni Brendish and Dr. Simon Green.

Toni has more than 30 years' experience, including over 20 years in CEO or Managing Director roles, predominantly working for blue chip fast-moving consumer goods, services and telecommunication companies. She has extensive experience in manufacturing, supply chain and regulatory management of infant formula markets across Asia, Australia, New Zealand, China and Europe.

Simon has 30 years of experience in the biotechnology industry focused on the discovery, development and commercialisation of life saving medicines. He was actively involved in CSL's global expansion and held roles as Senior Vice President in R&D and manufacturing operations.

Mr Harrington says he "welcomes the addition of the diverse experience to the board that Toni and Simon bring, and looks forward to their contribution to the future growth of Clover."

For further information, please contact:

Mr Rupert Harrington - Chairman Clover Corporation +61 3 8347 5000

Mr Peter Davey - MD & CEO Clover Corporation +61 3 8347 5000

About Clover Corporation Limited

Clover Corporation is an Australian company listed on the Australian Stock Exchange (ASX:CLV). Clover evolved from being a research and development, manufacturing and marketing company to one concentrating on forming strategic relationships focused on technology, new product development and commercialisation.

Clover's superior microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods and beverages. Developed through extensive research and development, our proprietary technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. All Clover products reach the highest standards of purity, stability and performance, allowing our customers to deliver consistent, high quality nutritional products to consumers.

For more information about Clover visit www.clovercorp.com.au

This is an excerpt of the original content. To continue reading it, access the original document here.